Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function
NCT ID: NCT01650987
Last Updated: 2016-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
72 participants
OBSERVATIONAL
2009-05-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)
NCT02428842
Analysis of the Results of Treatment for Cervical Carcinoma in Limburg
NCT01059695
Feasibility of Pet-scan at Day 1 of Brachytherapy for Patients With Cervical Cancer
NCT03315351
Sparing of Organs at Risk in High Dose Rate Brachytherapy
NCT01681342
Biomarkers for Clinical Hypoxia Evaluation in Cervical Cancer
NCT05029258
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Col 1
Patient with uterus adenocarcinoma, treated by surgery, then surveillance without complementary treatment
No interventions assigned to this group
Col 2
Patient with uterus adenocarcinoma, treated by surgery then adjuvant radiotherapy
No interventions assigned to this group
Col 3
patient with uterus adenocarcinoma, treated by surgery then curietherapy of vaginal dome
No interventions assigned to this group
Endometrial 4
patient with cervix carcinoma stage IA2 to IIB, treated by surgery only
No interventions assigned to this group
endometrial 5
patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy
No interventions assigned to this group
endometrial 6
patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy and radiotherapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With a corpus uteri adenocarcinoma, no metastatic, treated by:
* Surgery and observation without complementary treatment
* Or surgery and adjuvant radiotherapy
* Or Surgery and curietherapy of vaginal dome
* With a cervix carcinoma, stade IA2 to IIB proximal, treated by :
* External radiochemotherapy and curietherapy
* Or only surgery
* Or pre-surgical curietherapy and surgery
* Age \> 18 years
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Oscar Lambret
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philippe NICKERS, MD
Role: STUDY_DIRECTOR
Oscar Lambret Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Oscar Lambret
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SEXUTOX
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.